Stabilizers, Silencers, and Disease Stage: Lessons From Recent Trials of ATTR Cardiac Amyloidosis

https://doi.org/10.1016/j.jacc.2025.10.019Get rights and content

Refers to

Effect of Acoramidis on Recurrent and Cumulative Cardiovascular Outcomes in ATTR-CM

JACC, Volume 87, Issue 5, 10 February 2026, Pages 490-501

Ahmad Masri, Daniel P. Judge, Frederick L. Ruberg, Julian D. Gillmore, Justin L. Grodin, Laura Obici, Mathew S. Maurer, Marianna Fontana, Steen Hvitfeldt Poulsen, Peter van der Meer, Richard K. Cheng, Sarah A.M. Cuddy, Amrut V. Ambardekar, Kuangnan Xiong, Xiaofan Cao, Gillian Murtagh, Suresh Siddhanti, Adam Castaño, Jean-François Tamby, Jonathan C. Fox, Kevin M. Alexander, Ronald Witteles

View PDF

Access through your organization

Check access to the full text by signing in through your organization.

Section snippets

Funding Support and Author Disclosures

The authors have reported that they have no relationships relevant to the contents of this paper to disclose.